Short Term Trading Week Starting: 25 Oct, page-68

another quick one before i go to work.
EMD
chart looks like its setting up nicely , if it can break 27 there is no overhead resistance.

A bit if an overview on the company.

Emyria advances multiple drug registration programs; establishes pure cannabinoid delivery platform; secures exclusive rights to major MDMA-analogue library; clinical advisory strengthened

Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed clinical drug

development and care delivery company, is pleased to report on the Company's activities for the quarter ending September 30, 2021.

Highlights:

Launched development of a unique TGA- and FDA-compliant cannabinoid dose form with major US contract research organisation, Altasciences

Obtained exclusive access to a library of more than 100 novel MDMA analogues developed at the University of Western Australia (UWA); potential to develop multiple treatments targeting major psychiatric and neurological disorders; pre-clinical data of one MDMA analogue class shows potential in reducing symptoms associated with Parkinson's disease treatment

Boosted drug development and clinical advisory with addition of renowned neuropharmacologist, Dr. Mat Martin-Iverson and Consultant Psychiatrist and Pain Medicine Fellow-in-training, Dr. Jeremy Tannenbaum

Emyria well funded to accelerate drug development programs with $4.5M cash as of 30 Sep 2021, and a further $1.1M R&D tax incentive expected in Q2, FY21/22